ECOG-ACRIN EA9213: A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Objective

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

National Clinical Trial (NCT) Number: 05289687

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT05289687

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Hematology
• Leukemia

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]